Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jon David Hoppenfeld

Interventional Pain Medicine Charlotte, NC Medical Doctor

NPI 1336305473 CMS profile 1028005

2001 Randolph Rd, Charlotte, NC 28207

Open in the dashboard

General payments

$4,564

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jon David Hoppenfeld of Charlotte, NC is reported in the CMS Open Payments database as having received $4,564 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $911 33
2024 General $956 32
2023 General $1,346 28
2022 General $302 8
2021 General $198 6
2020 General $484 8
2019 General $367 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jon David Hoppenfeld
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jon David Hoppenfeld were reported at $911. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jon David Hoppenfeld Interventional Pain Medicine median Middle half National median
2019 $367 $684 $216–$2,079 $163
2020 $484 $382 $122–$1,109 $114
2021 $198 $552 $167–$1,554 $132
2022 $302 $605 $187–$1,924 $149
2023 $1,346 $671 $195–$1,915 $160
2024 $956 $684 $206–$1,837 $164
2025 $911 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,970 112 payments
  2. SPR Therapeutics, Inc $520 8 payments
  3. Nalu Medical, Inc. $32 1 payment
  4. Abbott Laboratories $22 1 payment
  5. Avanos Medical $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,564 123 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $2,200 56 payments
  2. SPRINT PNS System $520 8 payments
  3. SPECTRA WAVEWRITER Pain Management $471 7 payments
  4. General - Pain Management General - Pain Management_NMD $192 10 payments
  5. SPECTRA WAVEWRITER Pain Management $123 1 payment
  6. Intracept $45 2 payments
  7. WAVEWRITER ALPHA $40 3 payments
  8. GENERAL THERAPIES $36 2 payments
  9. GENERAL - PAIN MANAGEMENT Pain Management $35 2 payments
  10. Nalu Neurostimulation System $32 1 payment
  11. Other $122 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,536

Median for Pain Management: 951

Drug cost

$42,930

Median for Pain Management: $26,034

Branded share of claims

54.4%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 391 $11,092
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 335 $7,606
Oxycontin Oxycodone Hcl Brand 17 $6,272
Fentanyl Generic 44 $4,321
Oxycodone Hcl Generic 144 $2,419
Gabapentin Generic 93 $1,802
Morphine Sulfate Er Morphine Sulfate Brand 74 $1,782
Pregabalin Generic 50 $1,347
Morphine Sulfate Generic 36 $1,183
Duloxetine Hcl Generic 32 $926

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$69,976

Medicare's payments for the services billed

Medicare patients

256

Average age 73

Services billed

1,178

161 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 34%
Diabetes 31%
Ischemic heart disease 30%
Chronic kidney disease 29%
Osteoporosis 21%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record